Exane Derivatives’s Adaptimmune Therapeutics ADAP Stock Holding History

Exane Derivatives’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$206	Hold	121	–	–	﹤0.01%	671
2022 Q1	$249	Hold	121	–	–	﹤0.01%	941
2021 Q4	$454	Hold	121	–	–	﹤0.01%	778
2021 Q3	$626	Hold	121	–	–	﹤0.01%	916
2021 Q2	$468	Hold	121	–	–	﹤0.01%	947
2021 Q1	$642	Hold	121	–	–	﹤0.01%	773
2020 Q4	$652	Hold	121	–	–	﹤0.01%	715
2020 Q3	$966	Hold	121	–	–	﹤0.01%	622
2020 Q2	$1.21K	Hold	121	–	–	﹤0.01%	543
2020 Q1	$329	Hold	121	–	–	﹤0.01%	632
2019 Q4	$537	Hold	121	–	–	﹤0.01%	611
2019 Q3	$183	Hold	121	–	–	﹤0.01%	630
2019 Q2	$486	Hold	121	–	–	﹤0.01%	600
2019 Q1	$520	Hold	121	–	–	﹤0.01%	536
2018 Q4	$696	Hold	121	–	–	﹤0.01%	590
2018 Q3	$1.61K	Sell	121 -13,251	-99%	-$139K	﹤0.01%	509
2018 Q2	$160K	Hold	13,372	–	–	0.03%	281
2018 Q1	$135K	Buy	+13,372	New	+$117K	0.03%	268

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Exane Derivatives's ADAP Position: Q2 2022 in Review

Exane Derivatives held its Adaptimmune Therapeutics (ADAP) position steady in Q2 2022 at 121 shares worth $206. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Exane Derivatives first reported a position in ADAP in Q1 2018 and has held it in 18 quarters since. The position peaked at $160K in Q2 2018. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

Exane Derivatives held 121 shares of Adaptimmune Therapeutics worth $206 as of Q2 2022.
Exane Derivatives left its Adaptimmune Therapeutics share count unchanged in Q2 2022.
Adaptimmune Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #671 holding.
Exane Derivatives first reported a position in Adaptimmune Therapeutics in Q1 2018 and has held it in 18 quarters since.
Exane Derivatives's Adaptimmune Therapeutics position peaked at $160K in Q2 2018.
77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.